FOSUN PHARMA (02196) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

02196 FOSUN PHARMA

Watchlist

13.160
-0.260-1.94%

Market Closed Jan 10 16:08 CST

35.06BMarket Cap14.87P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

FOSUN PHARMA (02196): HENLIUS has received approval for a clinical trial of HLX4 combined with surufatinib injection for the treatment of patients with advanced/metastatic solid tumors.
FOSUN PHARMA (02196) announced that its holding subsidiary HENLIUS recently received notice from the National Medical Products Administration regarding...
Zhitong Finance05:23 ET
FOSUN PHARMA (02196.HK) holding subsidiary has obtained approval for pharmaceutical clinical trials.
On January 10, Gelonghui reported that FOSUN PHARMA (02196.HK) announced that its controlling subsidiary, Shanghai HENLIUS Biotechnology Co., Ltd. (hereinafter referred to as "the Company"), and its holding subsidiary (collectively referred to as "HENLIUS") recently received approval from the National Medical Products Administration (hereinafter referred to as "NMPA") for the use of HLX43 injection (i.e., a PD-L1 targeted antibody - novel DNA topoisomerase I inhibitor conjugate drug, registration classification: type 1 therapeutic Biological Product, hereinafter referred to as "HLX43") in combination with Surulni injection.
Gelonghui Finance05:22 ET
FOSUN PHARMA (600196.SH): The clinical trial application for injectable HLX43 has been approved.
FOSUN PHARMA (600196.SH) announced that its holding subsidiary HENLIUS Biotechnology Co., Ltd...
Zhitong Finance05:18 ET
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Zhitong Finance21:20 ET
Fosun Pharmaceutical's Unit Gets China Nod for Registration of Breast Cancer Drug
MT NewswiresJan 9 07:15 ET
Express News | Shanghai Fosun Pharma - Drug Registration Application for Fovinaciclib Citrate Capsules of Jinzhou Avanc Pharmaceutical Accepted by Nmpa
ReutersJan 9 05:02 ET

Comments

Spinee

Jun 24, 2024 21:45

HSI Opens Up 60 pts; LI AUTO & NIO Advance, as HENLIUS Rockets 21%

Hong Kong stocks opened higher in the morning. $Hang Seng Index (800000.HK)$opened 60 points or 0.3% higher at 18,088. $Hang Seng China Enterprises Index (800100.HK)$ opened 22 points or 0.3% higher at 6,463. $Hang Seng TECH Index (800700.HK)$ opened 11 points or 0.3% higher at 3,689.
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...

Spinee

Apr 25, 2023 11:34

HSI Slides 342 Pts; Techs & Pharmas Gloom

$Hang Seng Index (800000.HK)$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index (800100.HK)$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index (800700.HK)$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-W (09988.HK)$ dived 3.2% to $84.1.
$TENCENT (00700.HK)$ sank 1.9% to $338.4.
$MEITUAN-W (03690.HK)$ , $XIAOMI-W (01810.HK)$ , ...

Senorita Earnings

Mar 1, 2023 23:54

Columns Expert Meeting Minutes | Seven Development Trends of the China Medical Aesthetics Industry

Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...

Spinee

Dec 14, 2022 00:12

The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $FOSUN PHARMA (02196.HK)$ shares were opened 12% higher to 29 yuan.
$Pfizer (PFE.US)$ $AIM VACCINE (06660.HK)$

Spinee

Dec 6, 2022 21:36

In terms of allocation of Chinese stocks, it is suggested to focus on three main lines:

First, under the optimization of epidemic prevention, the repair market of damaged plates in the early stage, such as biomedical, aviation, wine travel and other plates;
Second, under the demand of stable growth, the industry policy margin is loose, such as the real estate industry chain and the Internet and other industries;
Third, under the theme of security for a long time, energy security, self contro...